Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Nexentis Completes Initial Computational Drug Screen

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

Israel

◆ Source

Read at stocktitan.net →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

Nexentis Technologies' subsidiary MitoCareX Bio has completed the initial computational screening stage of its AI-driven drug discovery initiative with Boltz, generating preliminary predictions that are encouraging but not yet experimentally validated. Further computational analysis and experimental validation are planned to determine if any candidates will advance.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

Your biotech project must now plan how to turn AI predictions into lab-proven drugs. The gap between computational hits and experimental proof is your next critical milestone to unlock funding and partnerships.

◆ Coverage

1 source · 26 Oct 2026

◆ Related on Wire

◆ Topics

Drug Discoveryai-drug-discoverycomputational-screeningbiotechpreclinicalvalidation